Oric Pharmaceuticals Inc

NASDAQ:ORICUnited States

ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in improving patients' lives by Overcoming Resistance In Cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its clinical-stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. ORIC-114, is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency towards exon 20 insertion mutations. ORIC-944 is an allosteric inhibitor of the polycomb repressive complex 2 (PRC2).

Contact Information

Headquarters

240 E. Grand Ave., 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-388-5600

Fax

302-655-5049

Executives

Independent Chairman of the Board

Richard Heyman

President, Chief Executive Officer, Director

Jacob Chacko

Chief Financial Officer

Dominic Piscitelli

Chief Medical Officer

Pratik Multani

Independent Director

Mardi Dier